You Searched For: Kanamycin+sulphate

Catalog Number: (CA209-4307)

Supplier: Rockland Immunochemical

Description: This product has been assayed against 1.0 µg of Human IgM in a standard capture ELISA using ABTS (2,2’-azino-bis-[3-ethylbenthiazoline-6-sulfonic acid])

Catalog Number: (10209-740)

Supplier: Boster Biological Technology

Description: Rabbit IgG polyclonal antibody for Interleukin-4(IL4) detection. Tested with WB in Human.

Supplier: VWR International

Description: Bilingual English/French laboratory notebooks feature user data, guidelines, table of contents, and documentation pages with researcher and witness signature blocks.

Supplier: QUALITY BIOLOGICAL, INC.

Description: RPMI 1640 is suitable for a wide range of anchorage independent cells. RPMI 1640 Medium is commonly supplemented with 10% Fetal Bovine Serum (FBS). Although, RPMI-1640 has been shown to support the serum-free growth of a number of cells.

Supplier: TRIFOREST ENTERPRISES INC

Description: TriForest shaker flasks are manufactured with virgin, optically clear, non leaching LEXAN® resin that retains clarity after gamma radiation.

Catalog Number: (CAD509-04-0050)

Supplier: Rockland Immunochemical

Description: Plasma is obtained from non-hemolyzed blood collected from healthy, fasted donors

Supplier: Heathrow Scientific

Description: High-quality, disposable tourniquets will not rope or curl during use.

Catalog Number: (100496-402)

Supplier: Electron Microscopy Sciences

Description: Sorensen's Phosphate Buffer is also know as phosphate mixed sodium salts. The osmolarity of a 0.1 M at a pH 7.2 is 226 mosmols; with the addition of 0.18 M of sucrose to the solution, the osmolarity raises to 425 mosmols.

Catalog Number: (CA202-4307)

Supplier: Rockland Immunochemical

Description: This product has been assayed against 1.0 µg of Cat IgM in a standard capture ELISA using ABTS (2,2’-azino-bis-[3-ethylbenthiazoline-6-sulfonic acid])

Catalog Number: (10664-200)

Supplier: Bioss

Description: G0S2 is a 103 amino acid novel target of peroxisome proliferator-activated receptors (PPARs) and regulator of latent HIV. G0S2 may be involved in adipocyte differentiation and its expression is essential for committing cells to enter the G1 phase of the cell cycle. G0S2 contains a CpG-rich island and multiple sites for potential phosphorylation by casein kinase II and protein kinase C. The gene encoding G0S2 maps to human chromosome 1, which is the largest human chromosome. Chromosome 1 spans about 260 million base pairs and makes up 8% of the human genome. There are about 3,000 genes on chromosome 1, and considering the great number of genes there are also a large number of diseases associated with chromosome 1. Notably, the rare aging disease Hutchinson-Gilford progeria is associated with the LMNA gene which encodes lamin A. Stickler syndrome, Parkinsons, Gaucher disease and Usher syndrome are also associated with chromosome 1. Aberrations in chromosome 1 are found in a variety of cancers including head and neck cancer, malignant melanoma and multiple myeloma.

Catalog Number: (CA82602-478)

Supplier: MilliporeSigma

Description: Recognizes the ~72 kDa Syk protein phosphorylated at Tyr525/526 in human Syk or Tyr519/520 in mouse Syk in 293T cells expressing wild-type Syk and CD8.

Catalog Number: (77439-296)

Supplier: Bioss

Description: The tumor suppressor gene RASSF1A (3p21.3), human Ras association domain family 1A, is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, small intestine, colon, and peripheral blood leukocytes. RASSF1A expression is inhibited by hypermethylation of the CpG island including the promoter and early transcribed regions of the human RASSF1A gene. Hypermethylated RASSF1A promoter is observed in primary tumors. Furthermore, RASSF1A is related with cell cycle regulation, apoptosis and microtubule stability. Potential tumor suppressor. Isoform A interacts with CDC20, an activator of the anaphase-promoting complex, APC, resulting in the inhibition of APC activity and mitotic progression. More specifically, RASSF1a inhibits proliferation by negatively regulating cell cycle progression at the level of G1/S-phase transition by regulating accumulation of cyclin D1 protein. It also inhibits the activation of STK3 and STK4 and may play an additional role as a scaffold protein, directing these enzymes to sites of activation. Isoform C has been shown not to perform these roles, and no function has been identified for this isoform.

Catalog Number: (102830-376)

Supplier: BioVendor

Description: Quality control test, Indirect ELISA – to determine titer of the antibody , SDS PAGE – to determine purity of the antibody, and BCA - to determine quantity of the antibody.

Supplier: Globe Scientific

Description: Globe scientific microscope slides are produced from premium glass sheets and offer exceptional quality while providing considerable savings.

Catalog Number: (10403-732)

Supplier: Bioss

Description: Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14. PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin. Ligand for integrinv/beta3 on the surface of blood vessels. Isoform 2: Mediates the proteolysis of CHUK/IKKA and initiates a primary innate immune response by inducing mitochondrial-nuclear stress signaling with activation of the pro-inflammatory NF-kappaB, NFAT and IRF transcriptional pathways.

Supplier: Adipogen

Description: In recent years several groups have studied the sequence requirements, specificity, signaling pathways and kinetics of the TLR (Toll-like receptor) 9 suppression by inhibitory oligonucleotide motifs, which led to a class of novel inhibitory oligonucleotide (iODNs), that is independent of the previously thought species preference. Subsequently it has been discovered that telomeric DNA repeats (TTAGGG)n can block immune activation by CpG-ODNs. Short, 11-15 base long oligonucleotides were synthesized that were capable of potently inhibiting CpG-stimulation. The optimal inhibitory DNA motif consists of a pyrimidine-rich triplet, preferably CCT, which is positioned 5- to the GGG sequence in a singlestranded DNA molecule. Additionally, both the optimal spacing between the CCT and GGG motifs, as well as their relative order to each other, is of crucial importance for the inhibitory DNA action. Interestingly, although both TLR7/TLR8 ligands and bacterial DNA share the endosomal compartment for receptor binding and signal transduction, certain iODNs (G-type) suppress only TLR9-mediated activation, whereas prototype class I iODN may also interfere with the activation via the TLR7/TLR8 pathway. Recently, intriguing evidence has been presented that for some iODN classes the immuno-modulatory biological activity shows only limited sequence dependency or may not even involve TLR-mediated uptake and signaling pathways. For example iODNs of the class II are thought to act on immune activation through inhibition of STAT signaling and independent of TLR signaling via binding to a yet to be identified 'ODN-receptor'. Slightly modified phosphodiester versions of the most potent inhibitory ODNs were also able to profoundly block the immune activation of macrophages and just recently prove to be valuable tools for in vivo use in experimental animal models of inflammatory and auto-immune diseases. Based upon these recent insights the following classification for iODNs has been suggested: Class I: G-stretch ODNs: TLR9-specific competitors, some iODNs may also affect TLR7 and TLR8 signalingClass II: ODNs with telomeric repeats: TLR-independent inhibitors of STAT signaling (cellular uptake via an 'ODN receptor'?)Class III: Inhibitors of DNA uptake in a sequence independent mannerClass IV: Long phosphorothioate ODNs as direct competitors of TLR9 signaling in a sequence independent manner